Recent Blog Articles
Improving access to hearing aids
Can mindfulness change your brain?
Five lifestyle factors that can help prevent gastroesophageal reflux disease
Transient ischemic attacks: Varied symptoms, all important
5 inflammation-fighting food swaps
Is IBD an underrecognized health problem in minority groups?
Sickle cell disease in newborns and children: What families should know and do
COVID-19 vaccines for children and teens: What we do - and don’t - know
Happy trails: Take a hike, now
Sleep well — and reduce your risk of dementia and death
In Brief: Many drugs prevent fractures, but none is best, study finds
Many drugs prevent fractures, but none is best, study finds
Although many medications help prevent osteoporotic fractures, there's not enough evidence to say whether any one of them is superior. That's the conclusion of a systematic review by researchers at the Southern California/RAND Evidence-based Practice Center. The review — funded by the Agency for Healthcare Research and Quality (AHRQ), part of the U.S. Department of Health and Human Services — included 76 randomized trials and 24 meta-analyses (research that combines and analyzes the results of several other studies) evaluating bisphosphonates, calcitonin, calcium, estrogen, parathyroid hormone, selective estrogen receptor modulators (SERMs), testosterone for men, and vitamin D, in people with low bone density or osteoporosis. Findings were published in the Feb. 5, 2008, issue of Annals of Internal Medicine.
The report finds that spinal fractures are prevented by the bisphosphonates alendronate (Fosamax), etidronate (Didronel), ibandronate (Boniva), risedronate (Actonel), and zoledronic acid (Zometa; Reclast is now also approved) and also by calcitonin, estrogen, parathyroid hormone (Forteo), and the SERM raloxifene (Evista). Fosamax, Actonel, Zometa, estrogen, and Forteo prevent hip and other nonspinal fractures. Vitamin D can help, but the effects vary with dose, type, and other factors for both spine and hip fractures. The researchers conclude that no single agent has emerged as best, partly because comparative studies haven't lasted long enough or included an adequate number of subjects.
To continue reading this article, you must log in.
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.
- Research health conditions
- Check your symptoms
- Prepare for a doctor's visit or test
- Find the best treatments and procedures for you
- Explore options for better nutrition and exercise
I'd like to receive access to Harvard Health Online for only $4.99 a month.Sign Me Up
Already a member? Login ».
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles. No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.